AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 71 min read$TTRX

Turn updates investor presentation; Phase 2 AD topline due Q1 2027, $10.3M cash runways into Q3 2027

Turn Therapeutics updated its investor presentation, highlighting GX-03 clinical progress and a $10.3M cash balance as of June 30, 2026. The company expects Phase 2 topline results for atopic dermatitis in Q1 2027 and has a cash runway into Q3 2027. Key milestones include an FDA meeting in Q4 2026 and Phase 3 initiations in 2027. The presentation also details safety and efficacy signals, financials, and IP status.

Original reporting
tradingview.com
Published Oct 7, 2026, 10:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 10:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Turn updates investor presentation; Phase 2 AD topline due Q1 2027, $10.3M cash runways into Q3 2027 — source image
Source · tradingview.com
Decision brief

The 30-second read

$TTRXBullishMed
01

Why it matters

The 8‑K filing provides the first public disclosure of the updated cash position and upcoming trial readout timeline, offering fresh material for valuation models.

02

Market read

The filing adds new data points for a micro‑cap biotech, potentially influencing short‑term price action and longer‑term valuation.

03

What to watch

Potential dilution from future financing if cash burn exceeds runway before next milestones.

Relevance 8/10Novelty 8/10Timing: today

Background

Turn Therapeutics (TTRX) is a clinical‑stage biotech developing treatments for atopic dermatitis and onychomycosis.

Company-level read

Ticker impact

$TTRXBullishHigh confidence
Context

Turn Therapeutics filed an 8‑K updating its investor presentation with Phase 2 GX‑03 trial progress and a $10.3 M cash balance.

Expected impact

likely upward pressure as investors price in upcoming Phase 2 topline and FDA meeting milestones

Evidence & confidence

Clinical‑trial milestones and cash runway are material catalysts for a biotech; no negative news offsets this.

Market effects

Sector

Strengthens outlook for the atopic dermatitis biotech niche and may lift peer valuations.

Regional

Minimal regional impact; primarily relevant to US biotech investors.

Global

Limited global effect; only notable for investors tracking US biotech pipelines.

Counterpoint

What could challenge this read

If Phase 2 data miss expectations, the stock could face sharp downside despite cash runway.

Key entities

  • company
    Turn Therapeutics Inc.

    Biotech developer of GX‑03 and PermaFusion pipelines.

Read at source← All news

Related articles

OCT 23
$TTRXMed

WBB Securities upgrades Turn Therapeutics stock rating to hold

WBB Securities upgraded Turn Therapeutics (TTRX) to Hold from Sell, setting a $10.00 price target. The stock has fallen from $16.45 but is up over 200% in six months. WBB expects Phase 2 trial results in 2026, but sees challenges for small-cap life science firms. Lucid Capital Markets initiated coverage with a Buy rating and $24.00 target, citing GX-03's potential.

investing.com2 min
AUG 12
$TTRXMed

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Low

SEC EDGAR 8-K6 min
JUL 7
$TTRXMed

Turn Therapeutics stock rises on expanded dermatitis trial By Investing.com

Turn Therapeutics (TTRX) shares rose 3.8% premarket after expanding its GX-03 Phase 2 atopic dermatitis trial to a broader EASI severity population. The company completed an interim analysis and said efficacy was seen in mild-to-moderate patients (EASI 1.1–7.0), with 71.4% vs 33.3% vehicle achieving Week 4 vIGA-AD success. Final design targets ~120–135 patients; no treatment-related serious AEs reported.

investing.com3 min
JUN 2
$TTRXMedAI 8/10

Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.

rttnews.com7 min